DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Prior treatment

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to the informed consent and treatment initiation visit (V1) and throughout the duration of the study

Other illness

• Participants with type-1 diabetes

Age

• Age \< 18 years on the informed consent and treatment initiation visit (V1)

Other

• Participants who are pregnant or who become pregnant (or who plan to become pregnant) during the study period
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• The decision to switch from DPP4i treatment to commercially available oral semaglutide has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study
• Participant with last measurement of HbA1c \>= 7.5% at informed consent and treatment initiation visit (V1) or less than or equal to (\<=) 90 days before informed consent and treatment initiation visit (V1)
• Treatment naïve to insulin. An exception is short-term insulin treatment for acute illness for a total of \< 14 days